Long-term prophylaxis of hereditary angioedema with danazol  

作　　者：Yingyang Xu Yuxiang Zhi 

机构地区：[1]Department of Allergy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China [2]Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases,Beijing 100730,China [3]National Clinical Research Center for Dermatologic and Immunologic Diseases,Beijing 100730,China

出　　处：《Chinese Medical Journal》2022年第21期2642-2643,共2页中华医学杂志（英文版）

基　　金：National Natural Science Fund(No. 81472870);CAMS Innovation Fund for Medical Sciences (CIFMS)(No. 2016-I2M-1-002)

摘　　要：To the Editor:Hereditary angioedema(HAE)is a rare genetic disorder that is characterized by recurrent attacks of subcutaneous or submucosal swelling.[1]HAE may lead to life-threatening conditions,with a mortality rate of 9.6%to 11.5%in those who develop laryngeal edema.[2,3]The fundamental abnormality of HAE types 1 and 2 is the deficiency or dysfunction of C1 inhibitor(C1-INH),a multifunctional serine protease inhibitor,caused by mutation in its coding gene,SERPING1.[1]These two types are collectively referred to as C1-INH-HAE.

关 键 词：EDEMA MORTALITY COLLECTIVE 

分 类 号：R543[医药卫生—心血管疾病]